MediWound (MDWD) Competitors $18.53 -0.11 (-0.59%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$18.53 0.00 (0.00%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MDWD vs. URGN, NUVB, SION, SNDX, QURE, DNA, IMTX, ANAB, CRON, and XERSShould you be buying MediWound stock or one of its competitors? The main competitors of MediWound include Urogen Pharma (URGN), Nuvation Bio (NUVB), Sionna Therapeutics (SION), Syndax Pharmaceuticals (SNDX), uniQure (QURE), Ginkgo Bioworks (DNA), Immatics (IMTX), AnaptysBio (ANAB), Cronos Group (CRON), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. MediWound vs. Its Competitors Urogen Pharma Nuvation Bio Sionna Therapeutics Syndax Pharmaceuticals uniQure Ginkgo Bioworks Immatics AnaptysBio Cronos Group Xeris Biopharma MediWound (NASDAQ:MDWD) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership. Is MDWD or URGN more profitable? MediWound has a net margin of -110.45% compared to Urogen Pharma's net margin of -150.68%. MediWound's return on equity of -74.12% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets MediWound-110.45% -74.12% -30.92% Urogen Pharma -150.68%-97,487.15%-49.57% Do analysts recommend MDWD or URGN? MediWound presently has a consensus price target of $32.25, suggesting a potential upside of 74.04%. Urogen Pharma has a consensus price target of $32.86, suggesting a potential upside of 69.37%. Given MediWound's higher possible upside, analysts plainly believe MediWound is more favorable than Urogen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediWound 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Urogen Pharma 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to MDWD or URGN? In the previous week, Urogen Pharma had 13 more articles in the media than MediWound. MarketBeat recorded 13 mentions for Urogen Pharma and 0 mentions for MediWound. Urogen Pharma's average media sentiment score of 0.38 beat MediWound's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Overall Sentiment MediWound Neutral Urogen Pharma Neutral Do insiders and institutionals hold more shares of MDWD or URGN? 46.8% of MediWound shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 9.2% of MediWound shares are owned by company insiders. Comparatively, 5.1% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, MDWD or URGN? MediWound has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Which has higher earnings & valuation, MDWD or URGN? MediWound has higher earnings, but lower revenue than Urogen Pharma. MediWound is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediWound$19.21M10.42-$30.22M-$2.09-8.87Urogen Pharma$90.40M9.91-$126.87M-$3.18-6.10 SummaryMediWound and Urogen Pharma tied by winning 8 of the 16 factors compared between the two stocks. Get MediWound News Delivered to You Automatically Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDWD vs. The Competition Export to ExcelMetricMediWoundMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$201.46M$2.46B$5.48B$9.51BDividend YieldN/A1.81%4.73%4.08%P/E Ratio-8.878.9728.6723.80Price / Sales10.42437.63373.9066.65Price / CashN/A157.7635.4557.96Price / Book6.414.838.275.55Net Income-$30.22M$31.62M$3.24B$259.03M7 Day Performance-8.85%-5.28%-3.69%-4.59%1 Month Performance-3.09%4.38%4.33%4.46%1 Year Performance6.01%-2.49%25.95%18.03% MediWound Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDWDMediWound1.9294 of 5 stars$18.53-0.6%$32.25+74.0%+6.1%$201.46M$19.21M-8.8780URGNUrogen Pharma4.6169 of 5 stars$18.90-0.3%$32.86+73.8%+22.6%$875.52M$90.40M-5.94200News CoverageUpcoming EarningsInsider TradeGap DownNUVBNuvation Bio2.2828 of 5 stars$2.55+2.0%$7.17+181.0%-37.4%$850.66M$7.87M-1.0960News CoverageUpcoming EarningsSIONSionna TherapeuticsN/A$19.85+3.9%$38.50+94.0%N/A$842.78MN/A0.0035Positive NewsLockup ExpirationSNDXSyndax Pharmaceuticals3.5579 of 5 stars$9.57-0.6%$34.10+256.3%-54.6%$828.64M$23.68M-2.48110Upcoming EarningsQUREuniQure2.4186 of 5 stars$14.98-0.9%$37.82+152.5%+83.0%$827.66M$27.12M-3.41500Trending NewsEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionDNAGinkgo Bioworks1.1775 of 5 stars$13.94-0.1%$8.50-39.0%N/A$817.10M$227.04M-1.52640News CoverageGap DownIMTXImmatics2.1547 of 5 stars$6.67+1.7%$14.67+119.9%-45.1%$797.37M$144.15M-39.23260ANABAnaptysBio2.2241 of 5 stars$26.59-1.3%$47.13+77.2%-27.6%$791.51M$91.28M-5.48100News CoveragePositive NewsUpcoming EarningsCRONCronos Group2.3244 of 5 stars$2.06+0.5%N/A-17.0%$790.65M$117.61M15.85450Upcoming EarningsXERSXeris Biopharma3.383 of 5 stars$5.07+1.0%$6.25+23.3%+121.4%$785.05M$203.07M-16.90290News CoveragePositive NewsUpcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies Urogen Pharma Alternatives Nuvation Bio Alternatives Sionna Therapeutics Alternatives Syndax Pharmaceuticals Alternatives uniQure Alternatives Ginkgo Bioworks Alternatives Immatics Alternatives AnaptysBio Alternatives Cronos Group Alternatives Xeris Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDWD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediWound With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
